Sodium benzoate - SyneuRx

Drug Profile

Sodium benzoate - SyneuRx

Alternative Names: Benzoate - SyneuRx; Clozaben; NaBen; SND-11; SND-12; SND-13; SND-14

Latest Information Update: 25 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SyneuRx International (Taiwan) corp
  • Class Antifungals; Antipsychotics; Antiseptics; Benzoates
  • Mechanism of Action D amino acid oxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Schizophrenia
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Schizophrenia
  • Clinical Phase Unknown Dementia

Most Recent Events

  • 04 Apr 2017 Clinical trials in Dementia in USA (PO) before April 2017
  • 04 Apr 2017 US FDA approves IND application for SND 14 in Dementia
  • 04 Apr 2017 SyneuRx plans a phase II/III trial for Dementia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top